CombiMatrix to Present At Baird 2009 Health Care Conference

CombiMatrix Corporation (Nasdaq:CBMX) today announced Dr. Amit Kumar, President and CEO, will present at the Robert W. Baird & Co. 2009 Health Care Conference, which will be held at the Four Seasons Hotel New York, 57 East 57th Street, New York, NY. Dr. Kumar's presentation will take place on Wednesday, September 9, 2009, at 12:15 p.m. (Eastern).

To attend the live webcast of Dr. Kumar's presentation, please go to http://www.wsw.com/webcast/baird9/cbmx/. You may also listen to the webcast by going to CombiMatrix's website at http://investor.combimatrix.com/events.cfm. The webcast will be archived for 90 days following the live presentation.

ABOUT ROBERT W. BAIRD & CO.

Baird is an employee-owned wealth management, capital markets, asset management and private equity firm with client assets of more than $66 billion. Leveraging our deep expertise and broad skills, we're dedicated to providing the best advice and service to our individual, corporate, institutional and municipal clients.

ABOUT COMBIMATRIX CORPORATION

CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. Combimatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory. Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: CombiMatrix Corporation

CONTACT:  CombiMatrix Corporation
Amit Kumar, Ph.D., President & CEO
(425) 493-2000
Fax: (425) 493-2010
Hayden IR
Investor Relations Contact:
Jeffrey Stanlis, Partner
(602) 476-1821
jeff@haydenir.com

Related terms: annual report, biotechnology, business, california, ceo, clinical, conference, corporate, defense, health, homeland security, hotel, nasdaq, new york, president, Private Equity, products, sec, securities, technology